Gilead Sciences, Inc. to Post Q2 2024 Earnings of $1.40 Per Share, Zacks Research Forecasts (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research reduced their Q2 2024 earnings per share estimates for shares of Gilead Sciences in a note issued to investors on Tuesday, April 23rd. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings per share of $1.40 for the quarter, down from their previous forecast of $1.54. The consensus estimate for Gilead Sciences’ current full-year earnings is $5.24 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.12 EPS, Q1 2026 earnings at $1.43 EPS and FY2026 earnings at $7.18 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period last year, the company earned $1.37 EPS. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year.

A number of other equities research analysts have also weighed in on GILD. Cantor Fitzgerald cut their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Mizuho cut their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Royal Bank of Canada cut their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Finally, Barclays lowered their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $84.57.

Gilead Sciences Price Performance

Shares of GILD stock opened at $65.27 on Wednesday. The firm has a market cap of $81.27 billion, a P/E ratio of 14.50, a P/E/G ratio of 0.96 and a beta of 0.19. Gilead Sciences has a fifty-two week low of $65.09 and a fifty-two week high of $87.86. The business’s 50 day moving average price is $71.40 and its 200-day moving average price is $76.32. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Nilsine Partners LLC raised its stake in shares of Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. grew its holdings in shares of Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 128 shares during the period. Financial Counselors Inc. grew its holdings in shares of Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 128 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC grew its holdings in shares of Gilead Sciences by 10.3% in the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 140 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.72%. Gilead Sciences’s payout ratio is presently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.